This disclosure relates to methods of authorizing distribution ofcomplement-inhibiting drugs to patients who have a complement-associateddisorder in a manner toensure that the patients are aware of the possible dangers of discontinuingtreatment withthe drugs. A database is prepared comprising patient information includingexperiencingadverse clinical events after discontinuing the drug treatment. Theinformation in thedatabase is collected and may be reported. The patients are given a warning asto adverseevents that may occur if treatment with the complement inhibiting drugs isdiscontinued.
